Effect of Jaeumgeonbi-Tang on Chronic Subjective Dizziness
NCT ID: NCT05482828
Last Updated: 2023-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
50 participants
INTERVENTIONAL
2010-05-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Herbal Medication (Gongjin-dan) for Chronic Dizziness
NCT03219515
Evaluation of the Efficacy and Safety of Herbal Medicine for Treating Work-related Chronic Low Back Pain
NCT02988232
Evaluation of Efficacy and Safety of Single and Multiple Therapy of Herbal Medicine/Chuna Therapy on Non-specific Chronic Low Back Pain: A Study Protocol for Multicenter, 3-arm, Randomized, Single Blinded, Parallel Group, Incomplete Factorial Design, Pilot Study -
NCT03132974
Evaluation of Effectiveness and Safety of Korean Herbal Medicine for Post-accident Syndromes After Acute Phase
NCT05494008
Efficacy and Safety of Red Ginseng Concentrated Powder on Improvement of Blood Triglyceride Level
NCT03828188
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* This design of the study is a randomized, double-blind, parallel-group, placebo-controlled design.
* Symptoms and quality of life of chronic subjective dizziness patients will be evaluated.
* Dizziness severity and quality of life of the patients will be evaluated using DHI (Dizziness Handicap Inventory) (1) before treatment (baseline), (2) after 2 weeks, and (3) after 4 weeks of JGT treatment.
* Blood samples of the patients will be gathered before and after JGT treatment for pathophysiological analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JGT group
Treatment group: JGT (Jaeumgeonbi-Tang) tablet. 8 g t.i.d. for 28 days
JGT (Jaeumgeonbi-Tang) tablet
JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
Placebo group
Placebo group: Corn starch tablet, 8 g t.i.d. for 28 days
Placebo tablet
Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JGT (Jaeumgeonbi-Tang) tablet
JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
Placebo tablet
Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* DHI (Dizziness Handicap Inventory) score ≥ 24
* Those who can fully comprehend the general protocol of this study and voluntarily agree to participate
Exclusion Criteria
* Dizziness secondary to specific diseases such as hypoglycemia, recent stroke (within the last 6 months), or heart disease.
* Use of medications that could influence the result of the study (anticonvulsants, sedatives, antidepressants, sleeping pills, prostate medicine, Parkinson's drug, dementia drug, etc.)
* Pregnancy, breastfeeding, or plans of becoming pregnant
* Functional dyspepsia (persistent, recurring abdominal pain, or discomfort)
* Other allergic diseases
* Ineligibility for other reasons in the opinion of the research clinician (when the physician determines that there are significant physical or mental defects that the patient cannot understand and follow the protocol)
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea Health Industry Development Institute
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
HoRyong Yoo
Associate Professor, Daejeon University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yoo HoRyong, KMD, PhD
Role: STUDY_DIRECTOR
Daejeon University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Daejeon Korean Medicine Hospital of Daejeon Unversity
Daejeon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B100013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.